{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:39:13Z","timestamp":1791441553557,"version":"4.3.3"},"reference-count":33,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To estimate the prevalence and predictors of sustained remission (SR) in patients with psoriatic arthritis (PsA) receiving biologic or targeted synthetic disease-modifying antirheumatic drugs (b\/tsDMARDs) in Sweden.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All patients with PsA initiating b\/tsDMARDs and who were registered in the national Swedish Rheumatology Quality Register (SRQ) from April 1999 to December 2019 were included. Data on disease\/treatment characteristics at first b\/tsDMARD (baseline) initiation and all subsequent visits were extracted from the SRQ. Remission was defined as Disease Activity Score in 28 joints based on C-reactive protein (DAS28-CRP) \u2264 2.6, Disease Activity Index for Psoriatic Arthritis in 28 joints (DAPSA28) \u2264 4 or the physician global assessment of disease activity (PGA) on a scale of 0 to 4 (remission = 0), and SR when these criteria persisted during \u2265 2 consecutive visits for \u2265 6 months. Baseline predictors of SR were explored using logistic regression analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data on 4669 patients with PsA with 48,773 visits were available. Eighty-one percent of patients achieved DAS28-CRP remission ever, and 54% achieved SR at least once. The corresponding percentages for DAPSA28 were 46% and 24% and for PGA were 69% and 38% for ever reaching remission and SR, respectively. Male sex was a positive predictor of reaching SR when measured by DAPSA28 and PGA but not by DAS28-CRP. Fewer swollen joints at baseline predicted SR according to all 3 remission criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A considerable proportion of patients with PsA receiving various b\/tsDMARDs never achieved remission, and approximately half never achieved SR in this Swedish nationwide registry study. Fewer swollen joints at first b\/tsDMARD initiation increases the likelihood of SR, regardless of remission criteria used. There was still a sex difference when measured with DAPSA28 and PGA, with men being more likely to reach SR.<\/jats:p>\n               <\/jats:sec>","DOI":"10.3899\/jrheum.2024-1250","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T08:20:12Z","timestamp":1747297212000},"page":"997-1004","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence and Predictors of Achieving Sustained Remission in Psoriatic Arthritis: A Swedish Nationwide Registry Study"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5295-2183","authenticated-orcid":false,"given":"Olafur","family":"Palsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3206-7050","authenticated-orcid":false,"given":"Jon T.","family":"Einarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4915-2924","authenticated-orcid":false,"given":"Johan K.","family":"Wallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2680-6120","authenticated-orcid":false,"given":"Thorvardur J.","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-6505","authenticated-orcid":false,"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7853-514X","authenticated-orcid":false,"given":"Meliha C.","family":"Kapetanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"2025100105301409000_52.10.997.1","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.3390\/jcm12113850","article-title":"Psoriatic arthritis: development, detection and prevention: a scoping review","volume":"12","author":"Kimak","year":"2023","journal-title":"J Clin Med"},{"key":"2025100105301409000_52.10.997.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150995"},{"key":"2025100105301409000_52.10.997.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2025100105301409000_52.10.997.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2025100105301409000_52.10.997.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150826"},{"key":"2025100105301409000_52.10.997.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025100105301409000_52.10.997.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"key":"2025100105301409000_52.10.997.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.01.012"},{"key":"2025100105301409000_52.10.997.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2025100105301409000_52.10.997.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213463"},{"key":"2025100105301409000_52.10.997.11","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00296-023-05376-5","article-title":"Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study","volume":"43","author":"Athanassiou","year":"2023","journal-title":"Rheumatol Int"},{"key":"2025100105301409000_52.10.997.12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000984"},{"key":"2025100105301409000_52.10.997.13","unstructured":"Swedish Rheumatology Quality Register . About us. [Internet. Accessed June 5, 2025.] Available from: https:\/\/srq.nu\/en\/about-us-health-professional\/"},{"key":"2025100105301409000_52.10.997.14","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/annrheumdis-2022-eular.1055","article-title":"POS1069 Coverage of the Swedish Rheumatology Quality register: to what degree are b\/tsDMARD treatments for psoriatic arthritis recorded? [abstract]","volume":"81","author":"DI Giuseppe","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025100105301409000_52.10.997.15","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i11"},{"key":"2025100105301409000_52.10.997.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00347-5"},{"key":"2025100105301409000_52.10.997.17","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2016.1220809"},{"key":"2025100105301409000_52.10.997.18","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00171-w"},{"key":"2025100105301409000_52.10.997.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204448"},{"key":"2025100105301409000_52.10.997.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"2025100105301409000_52.10.997.21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/rheumatology\/key054","article-title":"Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a nationwide study in Sweden","volume":"58","author":"Einarsson","year":"2019","journal-title":"Rheumatology"},{"key":"2025100105301409000_52.10.997.22","doi-asserted-by":"publisher","DOI":"10.1186\/ar3021"},{"key":"2025100105301409000_52.10.997.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131502"},{"key":"2025100105301409000_52.10.997.24","doi-asserted-by":"crossref","first-page":"e0266816","DOI":"10.1371\/journal.pone.0266816","article-title":"Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care","volume":"17","author":"Michelsen","year":"2022","journal-title":"PLoS One"},{"key":"2025100105301409000_52.10.997.25","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02380-z"},{"key":"2025100105301409000_52.10.997.26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40744-022-00445-w","article-title":"Responses to ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trials","volume":"9","author":"Eder","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025100105301409000_52.10.997.27","doi-asserted-by":"crossref","first-page":"105177","DOI":"10.1016\/j.jbspin.2021.105177","article-title":"Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: a multi-center study","volume":"88","author":"Duru\u00f6z","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2025100105301409000_52.10.997.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201972"},{"key":"2025100105301409000_52.10.997.29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/art.42758","article-title":"Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis: results from the European Spondyloarthritis Research Collaboration Network","volume":"76","author":"Hellamand","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025100105301409000_52.10.997.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0764"},{"key":"2025100105301409000_52.10.997.31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/rheumatology\/kead284","article-title":"Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries","volume":"63","author":"Linde","year":"2024","journal-title":"Rheumatology"},{"key":"2025100105301409000_52.10.997.32","doi-asserted-by":"crossref","first-page":"105744","DOI":"10.1016\/j.jbspin.2024.105744","article-title":"Intense symptoms of pain are associated with poor sleep, fibromyalgia, depression and sleep apnea in patients with rheumatoid arthritis and psoriatic arthritis. A register-based study","volume":"91","author":"Weman","year":"2024","journal-title":"Joint Bone Spine"},{"key":"2025100105301409000_52.10.997.33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10067-023-06850-y","article-title":"Similar levels of disease activity and remission rates in patients with psoriatic arthritis and rheumatoid arthritis\u2013results from the Finnish quality register","volume":"43","author":"Weman","year":"2024","journal-title":"Clin Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-1250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:31:07Z","timestamp":1759321867000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-1250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.3899\/jrheum.2024-1250"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-1250","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}